In young asymptomatic individuals with family history of premature ASCVD, elevated Lp(a) is related to higher CAC score, resulting in the identification of individuals with subclinical atherosclerosis.
Evolocumab significantly changes lipoprotein particle number and size, irrespective of concordance with LDL-c at baseline or disease status.
Prof. John Kastelein describes 3 major disturbances in lipoprotein metabolism contributing to CV risk. Novel therapies are being developed to address residual risk after LDL-c eradication.
Dr. Christopher Cannon explains the CV benefits of CETP inhibition in relation to non-HDL-c reduction
Dr. Samia Mora summarizes the challenges in lipid management with respect to testing and treatment.
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.
In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.
Men with LDL-C levels ≥190 mg/dL without atherosclerotic CVD, have a 2-fold higher risk of major CV events than would be predicted with a risk calculator.
AHA 2017 A new analysis of CANTOS dived into which patients may benefit most of canakinumab treatment. Baseline characteristics did not help, but response to treatment did.
AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.
AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP < 2 mg/L benefitted from a reduction in MACE and mortality, irrespective of the dose of canakinumab.